CYP4A22 Antibody (N-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP8785a
Background:
CYP4A22 catalyzes the omega-and (omega-1)-hydroxylation of various fatty acids such as laurate and palmitate. It shows no activity towards arachidonic acid and prostaglandin A1. This protein lacks functional activity in the kidney and does not contribute to renal 20-hydroxyeicosatetraenoic acid (20-HETE) biosynthesis.
Other Names:
Cytochrome P450 4A22, CYPIVA22, Fatty acid omega-hydroxylase, Lauric acid omega-hydroxylase, CYP4A22
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP8785a was selected from the N-term region of human CYP4A22. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CYP4A22
Gene ID: 284541
Primary Accession: Q5TCH4
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
CYP4A22 catalyzes the omega-and (omega-1)-hydroxylation of various fatty acids such as laurate and palmitate. It shows no activity towards arachidonic acid and prostaglandin A1. This protein lacks functional activity in the kidney and does not contribute to renal 20-hydroxyeicosatetraenoic acid (20-HETE) biosynthesis.
Other Names:
Cytochrome P450 4A22, CYPIVA22, Fatty acid omega-hydroxylase, Lauric acid omega-hydroxylase, CYP4A22
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP8785a was selected from the N-term region of human CYP4A22. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: CYP4A22
Gene ID: 284541
Primary Accession: Q5TCH4
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review